Improving drug development translation

The vast gap between basic drug research and clinical outcomes is being increasingly questioned. As we advance technologically in drug discovery, with new drug forms and biological agents becoming the norm, the translational capabilities of classic in vitro and in vivo models become increasingly strained.

The expression of human drug targets, enzymes, transporters, and interacting proteins on suitable tissues is critical for properly evaluating a drug candidate. Without them, candidates are more likely to be misclassified and put at risk or improperly eliminated from the pipeline in vitro.

CN Bio presents the application of the PhysioMimix OOC System in developing human and preclinical animal microphysiological systems to bridge the gap between in vitro, in vivo, and clinic risk evaluations in DILI. These technologies provide the ultimate translation tool, increasing confidence in moving candidates to successful clinical trials.

Watch the webinar to:

• Determine how human and preclinical animal liver MPS can predict DILI risk
• Understand the challenges of translation in medication development
• Identify the optimal application of MPS/OOC in the drug research and development process
• Discover the PhysioMimix human and preclinical animal liver MPS models, which accurately simulate liver function